fluvoxamine
Ligand Summary
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.
UNII: O4L1XPO44W
PubChem: 5324346
Guide to Pharmacology: 7189
ChEMBL: CHEMBL814
DrugCentral: 1230
LyCHI: CH1FF2M6Z9W4
Target Activities
10 Activities
Items per page:
1 – 10 of 10
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | ||||||
Kd | ||||||
Ki | ||||||
Ki | ||||||
IC50 | ||||||
Ki | ||||||
IC50 | ||||||
Ki | ||||||
Ki | ||||||
Ki | INHIBITOR | |||||